Lymfom non-Hodkinský B-buněčný
Doxycycline can inhibit matrix metalloproteinases (MMPs)
- Have antiangiogenic effects
- MMP9 expression seems particularly important in lymphoma
- Expression was increased in 50% of DLBCL
- Prognostic for poor survival
- Dogs with B-cell lymphoma
- MMP9 expression has been found to decrease with chemotherapy
- Inhibition of MMP9
- May thus have a therapeutic benefit in lymphoma
- Doxycycline may represent a means to achieve this goal
NF-kappaB
- Transcriptional regulator of MMPs
- Doxycycline has recently been shown to inhibit NF-kB in human DLBCL cells
Cell survival pathways were also altered
- Additivity or synergy with chemotherapeutics or targeted agents may ultimately be possible.
- Doxycycline concentrations of 2–6 ug/ml inhibited the proliferation of human DLBCL cells
- And xenograft tumors in mice
- Doxycycline concentrations within this range can be achieved in canine sera
B-cell lymfom u psů
- The most commonly recommended treatment regimen is a multidrug chemotherapy protocol with cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine, and prednisone (CHOP) (8, 10–13). Unfortunately, despite high remission rates, the majority of dogs will relapse and eventually die of their cancer within 1–2 years from the time of diagnosis. For B-cell lymphoma, the median survival times of 300–400 days are typically reported (14–16). CHOP chemotherapy is cost-prohibitive for many dog-owning families
